BISPHOSPHONATE TREATMENT AND ESOPHAGEAL DISEASE

Abstract

The problem of adverse reactions caused by the use of bisphosphonate is discussed. Gastrointestinal reactions that are observed in 20-30% of patients and a main reason for refusal to be treated are noted to be of considerable importance for real clinical practice. This aspect of bisphosphonate intolerability is being thoroughly investigated since some representatives of this drug group are able to induce very serious specific complications, such as esophageal ulcers, in addition to nonspecific symptoms (dyspepsia or gastralgia). The administration of novel drugs and formulations, careful consideration of risk factors in their prescription, clear use instructions, and timely monitoring the patients' status seem to assist in substantially reducing the risk of such reactions.